WHO CAN TURN $1 INTO $3? OTLK Outlook Therapeutics, Inc. $1.08-0.01 I find Eye Bios tricky- This is wet MD-- They have an Aug 29 FDA meeting...... for LYTENAVA for wet age-related macular degeneration/ A summer play for sure.... LYTENAVA could change the physician-prescribing paradigm given that Avastin is currently the most widely used wAMD treatment, even limited penetration into this market could still equate to significant revenue opportunities for Outlook.
APLS Apellis Pharmaceuticals, Inc.@$75.50 is up quite a bit (14%) but the buyout premium if it happens could be $90--$100 according to an analyst>>>>> There is risk of course-- what if no deal is happening. $75.48 +9.52 (+14.43%)11:44 AM 04/03/23 NASDAQ | $USD | Realtime
Is it true? You steal candy from babies? SCYNEXIS, Inc. (SCYX) Open at $3.03 NasdaqGM - NasdaqGM Real Time Price. 3.4100+0.4100(+13.67%)<---------- As of 11:47AM EDT.
Vol Analysis By Stoney- SCYX- "Oh shit" noon check in Volume-------->3,585,819 Avg. Volume-->1,436,736
True or Not True- (Bloomberg) -- Apellis Pharmaceuticals Inc., a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers, people with knowledge of the matter said. The company is speaking to advisers to consider its options amid the interest, they said. Apellis may also consider seeking partnerships or licensing agreements for some of its ophthalmology products, the people said, asking not to be identified discussing confidential information. Appellis rose 16% to $76.26 at 10:14 a.m. in New York trading Monday, giving it a market value of about $8.9 billion. The stock is up 30% in the past year. Deliberations are ongoing and there’s no certainty they will lead to a transaction, the people said. The company currently prefers to stay independent, two of the people said. A representative for Waltham, Massachusetts-based Apellis didn’t respond to requests for comment. In February, Apellis received approval from the US Food and Drug Administration for its treatment for an advanced eye disorder that’s a leading cause of blindness. The drug, Syfovre, is the first to win FDA approval for the treatment of geographic atrophy and is forecast to generate peak revenue of more than $1 billion, according to analyst estimates. Teaming up with another pharmaceutical company would give Apellis access to more resources and infrastructure to market and distribute Syfovre to US patients.
Deliberations are ongoing and there’s no certainty they will lead to a transaction, the people said. The company currently prefers to stay independent, two of the people said. Sounds wishy washy... but the analyst chirp in has me thinki8ng they must of gotten at least one offer that they don't like.
$6.73 high today now in a little bull flag-- Nine Energy Service, Inc. (NINE) NYSE - Nasdaq Real Time Price. 6.28+0.72(+12.95%)>----- Go Time! As of 11:56AM EDT.
Hey Bio-Lizard... Why didn't you catch this last week? When it was $1.60? Totally not criticizing... but how'd we miss it? They got an up front payment of $90M from this (below)... last years sales were, $5m. GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties SCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assets GSK plc (LSE/NYSE: GSK) and SCYNEXIS, Inc. (NASDAQ: SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC). This exclusive licence agreement gives GSK rights to commercialise Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection. Infectious diseases and HIV represent around two-thirds of GSK’s pipeline. Brexafemme complements GSK’s first or best-in-class portfolio alongside late-stage antibiotics gepotidacin, potentially the first novel antibiotic for uncomplicated urinary tract infections (uUTI) in over 20 years, and tebipenem, a potential new treatment of complicated urinary tract infections (cUTI). Luke Miels, Chief Commercial Officer, GSK said: “The challenge of antimicrobial resistance includes increasing rates of multi-drug resistant fungal infections. Brexafemme is a novel, approved antifungal medicine with a broad spectrum of activity against existing and emerging resistant strains of fungi. In addition, the transaction consolidates GSK’s synergistic portfolio of innovative late-stage antibiotics.” VVC affects up to 75% of women at least once, with 40-45% having two or more episodes1. Brexafemme has a distinct mechanism of action whereby it kills the fungus, as opposed to some antifungals which inhibit fungal growth. It is the only oral antifungal US FDA-approved treatment for VVC and reduction of RVVC. With rates of resistance to other antifungal treatments rising,Brexafemme addresses a clear unmet need for new oral treatments. David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS said: “This agreement represents a major milestone for SCYNEXIS, maximising Brexafemme’s commercial potential in VVC and further validating our vision of the critical role for this first-in-class antifungal in invasive infections. We are thrilled to partner with GSK on this high-potential asset and will continue progressing ibrexafungerp’s phase III programme in invasive candidiasis (IC).” IC is a life-threatening infection that affects the blood or internal organs. There are around 750,000 cases of IC every year worldwide.2 In the US, it is one of the most common causes of bloodstream infections in hospitalised patients and can lead to more extended hospital stays and higher associated costs. Financial terms Under the terms of the agreement, GSK will make an upfront payment to SCYNEXIS of $90 million, plus additional potential milestone-based payments totalling $503 million. GSK will pay up to $245.5 million if specific development, regulatory, and commercial milestones associated with the IC indication are successfully completed. A further $15 million milestone will be paid upon successful US FDA approval of an additional indication. GSK will pay sales-related milestone payments based on achieving a certain commercial performance of up to $242.5 million, and mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications (in both cases with the top tier based on achieving net sales greater than $1 billion).
Executive VP & COO dumped 1/3 of his shares last month in a non-scheduled sell. https://www.sec.gov/Archives/edgar/data/1532286/000089924323008430/xslF345X03/doc4.xml They have a lot of debt. Might work as trade, but I wouldn't hold it.